Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (534)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06398457 | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | recruiting | Early Phase 1 | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05035706 | Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors | active not recruiting | Early Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER |
| 1 |
| Sep 22, 2026 |
| clinicaltrials |
| NCT07676006 | A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Grit BiotechnologyINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07338357 | Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML | withdrawn | Early Phase 1 | 0 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07059975 | UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML | recruiting | Early Phase 1 | 36 | Baylor College of MedicineOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07771803 | A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)(Soursop) | recruiting | Early Phase 1 | 20 | Roger StrairOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07696481 | Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia(R/R AL) | not yet recruiting | Early Phase 1 | 18 | Zhujiang HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03568994 | Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)(ATACC AML) | completed | Early Phase 1 | 26 | Baylor College of MedicineOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03422731 | Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy | active not recruiting | Early Phase 1 | 82 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03964506 | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | recruiting | Early Phase 1 | 24 | Omar AljitawiOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07201727 | CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Oct 1, 2025 | clinicaltrials |
| NCT07144020 | Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia | recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07126782 | The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT | recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT03957915 | Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia(INA03) | completed | Early Phase 1 | 33 | Institut Paoli-CalmettesOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06980155 | XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia | recruiting | Early Phase 1 | 60 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT01822015 | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Early Phase 1 | 55 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06904859 | The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia | completed | Early Phase 1 | 50 | Shenzhen University General HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06201247 | Off-the-shelf CD123 CAR-NK for R/R AML | recruiting | Early Phase 1 | 12 | Peking University People's HospitalOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06110208 | Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML | terminated | Early Phase 1 | 3 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06786299 | Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia. | not yet recruiting | Early Phase 1 | 18 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06760260 | Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 7 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06762132 | A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 27 | Zhejiang UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06702098 | Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia(iNK-r/r AML) | not yet recruiting | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06642025 | EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 9 | Zhimin ZhaiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT02981914 | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation | completed | Early Phase 1 | 12 | University of ChicagoOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03224819 | Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) | terminated | Early Phase 1 | 46 | AmgenINDUSTRY | 3 | Sep 1, 2023 | clinicaltrials |
| NCT04923919 | Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia | unknown | Early Phase 1 | 100 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | terminated | Early Phase 1 | 2 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04484532 | Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers | completed | Early Phase 1 | 130 | Roswell Park Cancer InstituteOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT05744440 | Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT | unknown | Early Phase 1 | 12 | Xuzhou Medical UniversityOTHER | 1 | Feb 27, 2023 | clinicaltrials |
| NCT04518345 | TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia | completed | Early Phase 1 | 3 | Uma BorateOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05519384 | Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia | unknown | Early Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05252572 | Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05239689 | Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT05215015 | Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia | unknown | Early Phase 1 | 18 | Wuxi People's HospitalOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT01843634 | Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia | completed | Early Phase 1 | 10 | Jazz PharmaceuticalsINDUSTRY | 1 | Nov 10, 2021 | clinicaltrials |
| NCT04662294 | CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases | recruiting | Early Phase 1 | 108 | Zhejiang UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT03795779 | CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | May 19, 2021 | clinicaltrials |
| NCT04658004 | NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT02181478 | Intra-Osseous Co-Transplant of UCB and hMSC | completed | Early Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04599543 | IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT04209712 | Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease | unknown | Early Phase 1 | 6 | Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaINDUSTRY | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04321161 | Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment | completed | Early Phase 1 | 10 | University of FreiburgOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT00013533 | Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | completed | Early Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT04156256 | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT03291353 | Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia | withdrawn | Early Phase 1 | 0 | Michael BoyiadzisOTHER | 1 | Apr 19, 2019 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials